Volitionrx LTD (VNRX) financial statements (2021 and earlier)

Company profile

Business Address 13215 BEE CAVE PARKWAY
AUSTIN, TX 78738
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments17131022621
Cash and cash equivalents17131022621
Prepaid expense0000000
Other current assets0000000
Total current assets:18141122621
Noncurrent Assets
Finance lease, right-of-use asset(0)
Operating lease, right-of-use asset0
Property, plant and equipment3332100
Intangible assets, net (including goodwill)0011111
Intangible assets, net (excluding goodwill)0011111
Other undisclosed noncurrent assets0      
Total noncurrent assets:4443111
TOTAL ASSETS:21171525832
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3220111
Accounts payable110    
Accrued liabilities2111   
Other undisclosed accounts payable and accrued liabilities   (1)111
Debt10000  
Deferred revenue and credits 0000
Other undisclosed current liabilities0002020
Total current liabilities:4222131
Noncurrent Liabilities
Long-term debt and lease obligation3210   
Long-term debt, excluding current maturities2210   
Finance lease, liability1
Operating lease, liability0
Other undisclosed noncurrent liabilities0111100
Total noncurrent liabilities:3322100
Total liabilities:7554231
Stockholders' equity
Stockholders' equity attributable to parent, including:14121021601
Common stock0000000
Additional paid in capital104866662352012
Accumulated other comprehensive income (loss)00(0)(0)(0)(0)(0)
Accumulated deficit(90)(74)(56)(41)   
Other undisclosed stockholders' equity attributable to parent    (29)(20)(11)
Total stockholders' equity:14121021601
TOTAL LIABILITIES AND EQUITY:21171525832

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Other income  0  
Gross profit:0 0  0 
Operating expenses(16)(18)(15)(12)(10)(6)(5)
Other operating expense, net     (2) 
Other undisclosed operating income (loss)  (0)  2 
Operating loss:(16)(18)(15)(12)(10)(6)(5)
Nonoperating expense(0)   (0)  
Other nonoperating income (expense)0   (0)  
Interest and debt expense0(0)(0)    
Loss from continuing operations before income taxes:(16)(18)(15)(12)(10)(6)(5)
Income tax expense    (0)  
Loss before gain (loss) on sale of properties:(16)(18)(15)(12)(10)(6)(5)
Other undisclosed net loss(0)      
Net loss:(16)(18)(15)(12)(10)(6)(5)
Other undisclosed net income (loss) attributable to parent  000(2)1
Net loss available to common stockholders, diluted:(16)(18)(15)(12)(10)(8)(4)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(16)(18)(15)(12)(10)(6)(5)
Other comprehensive income (loss)(16) 0(0)0(0)(0)
Comprehensive loss:(32)(18)(15)(12)(10)(6)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 0000(2)1
Comprehensive loss, net of tax, attributable to parent:(32)(18)(15)(12)(10)(8)(4)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: